Table 3.
Univariate and multivariate analysis of overall survival in the patients classified into FIGO 2018 stage IIB.
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| (No. of patients) | HR | 95% CI | p value | HR | 95% CI | p value |
| Age (continuous) | 0.990 | 0.967–1.013 | 0.992 | 0.967–1.017 | ||
| Histology | ||||||
| SCC (211) | 1 (reference) | 1 (reference) | ||||
| nSCC (102) | 2.399 | 1.385–4.156 | 0.002 | 3.402 | 1.743–6.637 | < 0.001 |
| Tumor diameter | ||||||
| ≤ 40 mm (194) | 1 (reference) | 1 (reference) | ||||
| > 40 mm (116) | 2.548 | 1.452–4.471 | 0.001 | 2.988 | 1.599–5.584 | < 0.001 |
| LVSI | ||||||
| Negative (60) | 1 (reference) | 1 (reference) | ||||
| Positive (241) | 1.028 | 0.497–2.127 | 0.940 | 1.017 | 0.453–2.283 | 0.967 |
| Ovarian metastasis | ||||||
| Negative/preserved (307) | 1 (reference) | 1 (reference) | ||||
| Positive (3) | 6.425 | 1.556–26.522 | 0.010 | 2.935 | 0.621–13.868 | 0.174 |
| Corpus invasion | ||||||
| Negative (211) | 1 (reference) | 1 (reference) | ||||
| Positive (102) | 1.051 | 0.585–1.887 | 0.867 | 0.701 | 0.360–1.367 | 0.297 |
| Adjuvant therapy | ||||||
| CCRT (118) | 1 (reference) | 1 (reference) | ||||
| CT (57) | 0.906 | 0.394–2.084 | 0.816 | 0.680 | 0.285–1.623 | 0.385 |
| RT (99) | 1.437 | 0.765–2.697 | 0.259 | 1.490 | 0.727–3.055 | 0.276 |
| None (31) | 0.431 | 0.100–1.858 | 0.259 | 0.382 | 0.084–1.730 | 0.212 |
| CT | 1 (reference) | 1 (reference) | ||||
| RT | 1.585 | 0.702–3.581 | 0.267 | 2.191 | 0.889–5.399 | 0.088 |
| None | 0.476 | 0.101–2.240 | 0.347 | 0.561 | 0.116–2.702 | 0.471 |
| RT | 1 (reference) | 1 (reference) | ||||
| None | 0.300 | 0.070–1.280 | 0.104 | 0.256 | 0.056–1.181 | 0.081 |
FIGO The International Federation of Gynecology and Obstetrics, HR hazard ratio, CI confidence interval, SCC squamous cell carcinoma, nSCC non-squamous cell carcinoma, LVSI lymphovascular space invasion, CCRT concurrent chemoradiotherapy, CT chemotherapy, RT radiotherapy.